menu
    • menu
    [{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Trabedersen","moa":"||Transforming growth factor beta-2 mRNA","graph1":"Oncology","graph2":"Phase II","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mateon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mateon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Trabedersen","moa":"||Transforming growth factor beta-2 mRNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mateon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mateon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Oncotelic Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Trabedersen","moa":"||Transforming growth factor beta-2 mRNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mateon Therapeutics \/ Oncotelic Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Mateon Therapeutics \/ Oncotelic Therapeutics"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Trabedersen","moa":"Transforming growth factor beta-2 mRNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mateon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mateon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Trabedersen","moa":"Transforming growth factor beta-2 mRNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mateon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mateon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Trabedersen","moa":"Transforming growth factor beta-2 mRNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mateon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mateon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"Trabedersen","moa":"Transforming growth factor beta-2 mRNA","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mateon Therapeutics \/ Mateon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Mateon Therapeutics \/ Mateon Therapeutics"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Oncotelic Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Trabedersen","moa":"Transforming growth factor beta-2 mRNA","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mateon Therapeutics \/ Mateon Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Mateon Therapeutics \/ Mateon Therapeutics"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Trabedersen","moa":"Transforming growth factor beta-2 mRNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mateon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mateon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Oligonucleotide","year":"2020","type":"Partnership","leadProduct":"Trabedersen","moa":"Transforming growth factor beta-2 mRNA","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mateon Therapeutics \/ Mateon Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Mateon Therapeutics \/ Mateon Therapeutics"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||CB2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mateon Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Mateon Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TT-816","moa":"||CB2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mateon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mateon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Windlas Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Artemisinin","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mateon Therapeutics \/ Windlas Biotech","highestDevelopmentStatusID":"11","companyTruncated":"Mateon Therapeutics \/ Windlas Biotech"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Combretastatin A1 Diphosphate","moa":"Tubulin polymerisation","graph1":"Oncology","graph2":"Phase I","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mateon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mateon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Oceanpine Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"TT-702","moa":"A2BR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mateon Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Mateon Therapeutics \/ Oceanpine Capital","highestDevelopmentStatusID":"5","companyTruncated":"Mateon Therapeutics \/ Oceanpine Capital"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Autotelic Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Licensing Agreement","leadProduct":"Trabedersen","moa":"||Transforming growth factor beta-2 mRNA","graph1":"Oncology","graph2":"Preclinical","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mateon Therapeutics \/ Autotelic Bio","highestDevelopmentStatusID":"4","companyTruncated":"Mateon Therapeutics \/ Autotelic Bio"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Artemisinin","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mateon Therapeutics \/ Mateon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Mateon Therapeutics \/ Mateon Therapeutics"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Artemisinin","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mateon Therapeutics \/ Mateon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Mateon Therapeutics \/ Mateon Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Mateon Therapeutics

    Menu

    Mateon Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mateon Therapeutics

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed

                            Mateon Therapeutics

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TT-816,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Teon Therapeutics Announces Clinical Trial Collaboration With Merck to Evaluate TT-816, a Novel Oral Immune Re...

                            Details : Teon Therapeutics has entered into the clinical trial collaboration agreement with Merck for expansion clinical study and will evaluate Teon’s oral, immune response modifier, TT-816, in combination with Merck’s KEYTRUDA (pembrolizumab), for patients ...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 18, 2023

                            Lead Product(s) : TT-816,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mateon Therapeutics

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed

                            Mateon Therapeutics

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trabedersen

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Oncotelic Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oncotelic Presenting Data for OT101 Against Pancreatic Cancer (PDAC) at the SITC 37th Annual Meeting

                            Details : Anti-viral activity OT-101 (trabedersen), in an in vitro antiviral testing which has a 50% effective concentration of 7.6 µg/mL and is not toxic at highest dose of 1000 µg/mL giving safety index value of >130, is considered highly active and on par or ...

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            September 28, 2022

                            Lead Product(s) : Trabedersen

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Oncotelic Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Mateon Therapeutics

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed

                            Mateon Therapeutics

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TT-816,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Teon Therapeutics Announces First Patient Treated in Phase 1/2 Clinical Trial of TT-816, a Novel Oral Immune C...

                            Details : TT-816 is a first-in-class, oral cannabinoid CB2 receptor antagonist acting as an immune checkpoint inhibitor for the treatment of a broad range of solid tumors and is highly selective for the CB2 receptor versus the CB1 receptor.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 11, 2022

                            Lead Product(s) : TT-816,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Mateon Therapeutics

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed

                            Mateon Therapeutics

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Artemisinin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Windlas Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety and Efficacy of Artemisinin- a Herbal Supplement on COVID-19 Subjects

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 13, 2021

                            Lead Product(s) : Artemisinin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Windlas Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Mateon Therapeutics

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed

                            Mateon Therapeutics

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trabedersen,Artemisinin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Oncotelic Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mateon’s Update on C001 - Global Study for Ot-101 Against Covid-19

                            Details : Mateon has completed the enrollment of its sentinel Part 1 and Part 2 COVID-19 patients which allows for the continuing expansion to the targeted 18 patients in part 1 and 18 patients in part 2. OT-101 is an antisense against the host TGF-β protein.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            August 03, 2021

                            Lead Product(s) : Trabedersen,Artemisinin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Oncotelic Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Mateon Therapeutics

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed

                            Mateon Therapeutics

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TT-702

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Oceanpine Capital

                            Deal Size : $30.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Teon Therapeutics Completes $30 Million Series A Financing

                            Details : The funds will be used to advance the company’s lead A2BR-selective antagonist TT-702 into the clinic as well as to build the company’s pipeline.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 23, 2021

                            Lead Product(s) : TT-702

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Oceanpine Capital

                            Deal Size : $30.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Mateon Therapeutics

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed

                            Mateon Therapeutics

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trabedersen,Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mateon’s Global Study for OT-101/ Tgf-Β Inhibitor Against Covid-19 Enrolls and Treats Its First Patient

                            Details : C-001 is a Phase 2 randomized, placebo-control study to evaluate safety and efficacy of OT-101 in combination with standard of care on two patient cohorts – 1) mild or moderate disease, and 2) severe disease requiring mechanical ventilation or intubati...

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            December 30, 2020

                            Lead Product(s) : Trabedersen,Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Mateon Therapeutics

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed

                            Mateon Therapeutics

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trabedersen,Aldesleukin

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Autotelic Bio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Mateon Announces Achievement of Milestone Under Licensing of OT-101/IL-2 Combination to Autotelic BIO

                            Details : OT-101 has demonstrated robust efficacy against pancreatic cancer, glioblastoma, and melanoma during phase 2 clinical trials. The demonstration that OT-101 will synergize with IL-2 further demonstrate its utility as adjunct to other immunotherapies.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            October 06, 2020

                            Lead Product(s) : Trabedersen,Aldesleukin

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Autotelic Bio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Mateon Therapeutics

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed

                            Mateon Therapeutics

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Combretastatin A1 Diphosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Granted Pediatric Disease Designation for OXi-4503

                            Details : OXi4503 in combination with standard chemotherapy drug cytarabine was generally well tolerated by adult AML patients and a maximum tolerated dose level of OXi4503 was identified as the recommended dose for further clinical development of this novel two-d...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 16, 2020

                            Lead Product(s) : Combretastatin A1 Diphosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Mateon Therapeutics

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed

                            Mateon Therapeutics

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Artemisinin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Recipient : Asili Research Alliance

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Mateon and Asili Research Alliance Enter Into Partnership for the Development of Artemisinin Against Covid-19

                            Details : ARTI19 is designed to rapidly establish the clinical efficacy of Artemisinin in mild and moderate COVID-19 patients. In-vitro, the medical grade version of the supplement has proven potency and safety similar to Remdesivir with an EC50 = 0.45 ug/ml and S...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 20, 2020

                            Lead Product(s) : Artemisinin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Recipient : Asili Research Alliance

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth